Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
November 07, 2022 08:05 ET
|
Lyell Immunopharma, Inc
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO,...
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
November 07, 2022 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
invIOs to present data from clinical stage Cbl-b program at SITC 2022
October 18, 2022 02:00 ET
|
invIOs GmbH
VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its...
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
October 05, 2022 08:00 ET
|
Codiak BioSciences, Inc.
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
September 28, 2022 08:55 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
November 15, 2021 09:05 ET
|
Morphic Therapeutic
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
November 12, 2021 07:09 ET
|
Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
November 12, 2021 07:07 ET
|
Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
November 12, 2021 07:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
November 12, 2021 07:00 ET
|
Adaptimmune Therapeutics plc
- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests...